AZD 9773
Alternative Names: AZD9773; CytoFabLatest Information Update: 05 Nov 2023
At a glance
- Originator Protherics
- Developer AstraZeneca; BTG; Protherics
- Class Polyclonal antibodies
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cardiovascular disorders; Coronary disorders; Crohn's disease; Graft-versus-host disease; Jarisch-Herxheimer reaction; Malaria; Septic shock; Transplant rejection
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 08 Aug 2012 Discontinued - Phase-II for Septic shock in Australia (IV)
- 08 Aug 2012 Discontinued - Phase-II for Septic shock in Belgium (IV)